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Background
To share our experience in second line Anti Retroviral
Therapy (ART) at State AIDS Clinical Expert Panel
(SACEP) Clinic, Centre of Excellence (CoE), ART Cen-
tre, B. J. Medical College, Civil Hospital, Ahmedabad,
Gujarat, India.
Methods
First line treatment failure Patients (as per Indian
National ART Guidelines) were referred to SACEP
Clinic for further evaluation and if eligible as per Indian
National 2
nd Line ART Guidelines; enrolled and fol-
lowed up for initiation of 2
nd Line ART at our institute.
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Table 1
Parameter Outcome
Total Patients referred to SACEP 127
Patients Eligible and referred for Plasma Viral Load (PVL) (n = 127) 122(96.06%)
Patients recommended 2
nd Line ART after PVL (n = 122) 75(61.47%)
Patients initiated Free 2
nd Line ART (n = 75) 69(92.0%)
Patients under follow up TB Treatment/Counseling to initiate 2
nd Line ART 6
Adherence Counseling for 2
nd Line ART Patients (n = 69) 69(100%)
Undetectable PVL (<400 copies/ml) after 6 months of 2
nd Line ART (n = 28) 24
Therapeutic Success according to Undetectable PVL (24/28) 85.74%
No. of Death after initiation of 2
nd Line ART (n = 69) 8(11.59%)
Death Analysis Cause of Death WHO Stage/PVL/CD4 n = 8
Accidental T3/560459/17 1
Renal Failure T3/208048/230 1
Malignancy T4/384469/38 1
Opportunistic Infections (OIs) T3/46453/67 4
T4/507495/26
T4/1166325/32
T4/289375/21
Unknown Reason T3/4095718/29 1
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Provision of Free 2
nd Line ART to People Living with
HIV/AIDS (PLHA) Program by National AIDS Control
Organization (NACO), India was started in November,
2008 under SACEP Clinic for Gujarat and Rajasthan
PLHAs. Till October 2009 total 127 1
st Line ART Fail-
ure patients were referred to SACEP Clinic, Table 1.
Discussion
Switching to 2
nd Line ART based on Immunological
Failure, Clinical Failure is not recommended; as out of
122 PLHAs analyzed only 75 PLHAs have Virological
Failure. Adherence Counseling for 2
nd Line ART helps
quite in reduction of PVL. Deaths analysis shows that
late switch to 2
nd Line ART at CD4 < 100 cells/mm
3
may not result in desired therapeutic goals.
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